Immunotherapy Study in Early-Stage Breast Cancer Patients
Author Information
Author(s): Apostolopoulos Vasso, Pietersz Geoffrey A, Tsibanis Anastasios, Tsikkinis Annivas, Drakaki Heleni, Loveland Bruce E, Piddlesden Sara J, Plebanski Magdalena, Pouniotis Dodie S, Alexis Michael N, McKenzie Ian F, Vassilaros Stamatis
Primary Institution: Burnet Institute at Austin, Heidelberg, Victoria, Australia
Hypothesis
Can immunotherapy using oxidized mannan-MUC1 prevent cancer recurrence in early-stage breast cancer patients?
Conclusion
The study suggests that MUC1 immunotherapy is beneficial in preventing recurrence in early breast cancer patients.
Supporting Evidence
- Patients receiving immunotherapy had no recurrences after 5.5 years.
- Four out of 15 patients receiving placebo had recurrences.
- Nine out of 13 patients receiving immunotherapy developed antibodies to MUC1.
Takeaway
This study tested a new treatment for early breast cancer that helps prevent the cancer from coming back, and it worked well for the patients who received it.
Methodology
A randomized, double-blind study where 31 patients received either placebo or oxidized mannan-MUC1 injections.
Potential Biases
Potential bias due to the small number of participants and lack of a control group receiving only oxidized mannan.
Limitations
The study had a small sample size and was a pilot study.
Participant Demographics
Postmenopausal women aged 51-81 with stage II breast cancer.
Statistical Information
P-Value
0.0292
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website